UiPath Inc. (NYSE:PATH) Shares Sold by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC lowered its position in shares of UiPath Inc. (NYSE:PATH) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,903 shares of the healthcare company’s stock after selling 2,218 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in UiPath were worth $966,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. 180 Wealth Advisors LLC lifted its holdings in shares of UiPath by 0.3% in the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock worth $4,497,000 after purchasing an additional 492 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in shares of UiPath by 4.9% in the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after acquiring an additional 598 shares during the period. Simplicity Solutions LLC lifted its position in UiPath by 4.9% in the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after purchasing an additional 598 shares during the last quarter. Arizona State Retirement System boosted its stake in UiPath by 0.8% during the 3rd quarter. Arizona State Retirement System now owns 97,951 shares of the healthcare company’s stock valued at $1,676,000 after purchasing an additional 733 shares during the period. Finally, Axxcess Wealth Management LLC grew its position in UiPath by 2.6% in the 3rd quarter. Axxcess Wealth Management LLC now owns 29,121 shares of the healthcare company’s stock worth $498,000 after purchasing an additional 740 shares during the last quarter. Institutional investors own 62.50% of the company’s stock.

UiPath Trading Up 0.9 %

NYSE:PATH opened at $19.48 on Friday. The stock has a fifty day simple moving average of $21.75 and a 200 day simple moving average of $21.65. UiPath Inc. has a 1-year low of $12.38 and a 1-year high of $27.87.

UiPath (NYSE:PATH) last announced its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The company had revenue of $405.25 million during the quarter, compared to analysts’ expectations of $383.32 million. Sell-side analysts anticipate that UiPath Inc. will post -0.04 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the completion of the sale, the chief financial officer now owns 87,505 shares in the company, valued at $1,998,614.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 72,000 shares of company stock worth $1,591,360. Corporate insiders own 31.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PATH. Barclays lifted their price target on UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday, March 15th. Mizuho lifted their target price on UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Thursday, March 14th. Morgan Stanley increased their price target on UiPath from $17.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 14th. Evercore ISI lifted their price objective on shares of UiPath from $24.00 to $27.00 and gave the company an “in-line” rating in a research note on Thursday, March 14th. Finally, Bank of America upped their price objective on shares of UiPath from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, UiPath presently has an average rating of “Moderate Buy” and an average price target of $27.41.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.